Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 4 2Phase 1 2

Status

Completed 4Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Sarcoma 6Gastrointestinal 6

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Leukemia, Myeloid, Chronic-Phase 12Leukemia 6Gastrointestinal Stromal Tumors 6Neoplasm Metastasis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Synovitis, Pigmented Villonodular 2Recurrence 2Ovarian Neoplasms 2Hematologic Diseases 2Blast Crisis 2Substance Withdrawal Syndrome 1Peritoneal Neoplasms 1Neoplastic Processes 1Neoplasm, Residual 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Glioma 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Imatinib Mesylate 27regorafenib 8nilotinib 6Sunitinib 6pazopanib 3Temozolomide 3Paclitaxel 3Nivolumab 3Ipilimumab 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3trametinib 2spartalizumab 2ripretinib 2ponatinib 2envafolimab 2Specimen Handling 2Sorafenib 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Dasatinib 2Carboplatin 2CTLA-4 Antigen 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2vatalanib 1temsirolimus 1rubitecan 1romidepsin 1perifosine 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Stromal Tumors × nilotinib × Clear all
NCT01863745 2024-08-19

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Novartis

Phase 2 Completed
15 enrolled 7 charts
GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT00633295 2017-06-22

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Novartis

Phase 2 Completed
9 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
2 enrolled
GastrointestinalSarcoma

Disease Progression, Gastrointestinal Stromal Tumors

NCT00718562 2017-02-23

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Novartis

Phase 2 Completed
35 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00782834 2013-04-22

07060

Fox Chase Cancer Center

Phase 2 Terminated
13 enrolled 8 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01270893 2012-08-02

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡